Thoratec Announces $150 Million Share Repurchase Authorization
PLEASANTON, Calif., Nov. 26, 2012
PLEASANTON, Calif., Nov. 26, 2012 /PRNewswire/ -- Thoratec Corporation
(NASDAQ: THOR), a world leader in device-based mechanical circulatory support
therapies to save, support and restore failing hearts, announced today that
its Board of Directors has authorized the repurchase of up to $150 million of
the company's shares of common stock. The company's prior authorization
expired in early November. As part of the new authorization, the company has
entered into a $75 million Accelerated Share Repurchase (ASR) agreement with
J.P. Morgan, which will begin immediately. The balance of the authorization
will be available for utilization at the company's discretion through the end
Under the ASR agreement, Thoratec will receive approximately 1.5 million
shares at the inception of the program. The total number of shares ultimately
purchased under the agreement will be determined upon final settlement, using
the volume-weighted average price of the Company's common stock over a period
of time of up to 4.5 months.
"We remain enthusiastic about the future for Thoratec, based on our market
opportunity in both chronic and acute circulatory support, our competitive
position, and our pipeline of new technologies. This repurchase authorization
reflects our confidence in the long-term strength of the company, as well as
our commitment to a disciplined capital deployment strategy," said Gary F.
Burbach, President and Chief Executive Officer.
"While our top priority is to fund our internal growth initiatives and pursue
strategic opportunities, our current cash position coupled with ongoing strong
cash flow generation provides us the opportunity to continue returning value
to shareholders through additional share repurchase activity," added Taylor C.
Harris, Vice President and Chief Financial Officer.
During the first nine months of 2012, Thoratec generated $109 million of cash
flow from operating activities, an increase of over 25% relative to the
comparable period in 2011. As of September 29, 2012, the company had
approximately $308 million in cash, cash equivalents and investments.
Repurchases will take place on the open market or in privately negotiated
transactions from time to time based on market and other conditions. The
program is effective immediately, and except for the ASR, it may be modified,
suspended, terminated or extended by the company at any time without prior
Thoratec is the world leader in mechanical circulatory support with the
broadest product portfolio to treat the full range of clinical needs for
patients suffering from advanced heart failure. The company's products include
the HeartMate LVAS and Thoratec VAD, with more than 20,000 devices implanted
in patients suffering from heart failure. Thoratec also manufactures and
markets the CentriMag and PediMag / PediVAS product lines. Thoratec is
headquartered in Pleasanton, California. For more information, visit
Thoratec, the Thoratec logo, HeartMate and HeartMate II are registered
trademarks of Thoratec Corporation and IVAD is a trademark of Thoratec
Corporation. CentriMag and PediMag are registered trademarks of Thoratec LLC,
and PediVAS is a registered trademark of Thoratec Switzerland GmbH.
Many of the preceding paragraphs, particularly but not exclusively those
addressing guidance for fiscal 2012 financial results or future performance
contain forward-looking statements within the meaning of Sections 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
These statements can be identified by the words, "believes," "views,"
"expects," "plans," "projects," "hopes," "could," "will," and other similar
words. Actual results, events or performance could differ materially from
these forward-looking statements based on a variety of factors, many of which
are beyond Thoratec's control. Therefore, readers are cautioned not to put
undue reliance on these statements. Investors are cautioned that all such
statements involve risks and uncertainties, including risks related to
regulatory approvals, the development of new products, including development
and clinical trial timing, and new markets including Destination Therapy, the
growth of existing markets for our products, customer and physician acceptance
of Thoratec products, changes in the mix of existing markets for our products
and related gross margin for such product sales, the ability to improve
financial performance, the effects of FDA regulatory requirements, our ability
to address issues raised by FDA inspections adequately and on a timely basis
without a resulting recall of products or interruption of manufacturing or
shipment of products, the effects of healthcare reimbursement and coverage
policies, the effects of seasonality on Thoratec product sales, the effects of
competition and the effects of any merger, acquisition and divestiture related
activities. Forward-looking statements contained in this press release should
be considered in light these factors and those factors discussed from time to
time in Thoratec's public reports filed with the Securities and Exchange
Commission, such as those discussed under the heading, "Risk Factors," in
Thoratec's most recent annual report on Form 10-K, quarterly reports on Form
10-Q, current reports on Form 8-K and other SEC filings. These forward-looking
statements speak only as of the date hereof. Thoratec undertakes no obligation
to publicly release the results of any revisions to these forward-looking
statements that may be made to reflect events or circumstances after the date
hereof, or to reflect the occurrence of unanticipated events.
SOURCE Thoratec Corporation
Contact: Taylor Harris, Vice President and Chief Financial Officer,
Press spacebar to pause and continue. Press esc to stop.